A fixed 1:1 combination designed to produce superior, sustained weight loss (and, in type-2 diabetics, superior HbA1c reduction) versus either drug alone, by pairing two mechanistically distinct satiety pathways in one lockstep weekly regimen — this is Novo Nordisk's own designed and trial-tested purpose for the pairing, not a community-improvised stack.
Why it matters
Semaglutide (a GLP-1 drug) and cagrilintide (an amylin drug) each quiet hunger through a different, barely-overlapping brain pathway.
The published per-compound doses, timing, cycle length, the mechanism sources give for why it's combined, and the harm-reduction notes — the parts that took the most research to get right — are part of membership.
